The best Medical Affairs organizations are evolving from a support-only function to a strategic partner of the business. Explore a common set of Medical Affairs challenges with other leaders from Pharma, Biotech, and Medical Device companies.
The document discusses the role and responsibilities of Medical Affairs departments within pharmaceutical companies. It describes how Medical Affairs operates medical information functions, provides insights from research to brand teams, cultivates relationships with key opinion leaders, and oversees publication planning and medical writing. Medical Affairs contributes to promotional review and provides market intelligence. The functions of Medical Affairs are organized globally and sometimes by business unit or therapeutic area at the local level. Key areas of specialization within Medical Affairs include medical services, medical research, and medical liaisons.
Method, tools and recommendations to boost Medical Science Liaisons Competence and performance.
Presentation of best practices to manage key opinion leaders
Medical affairs department for small organizationDr. Zubair Ali
The document summarizes the drug development process and the role of medical affairs departments within pharmaceutical companies. It discusses the various phases of clinical drug trials from phase I to phase IV. It then outlines the structure and responsibilities of medical affairs, including clinical research, pharmacovigilance, medical information services, statistics management, and providing medical support to marketing and sales teams. A key part of medical affairs is the medical science liaison program which aims to educate medical professionals and support clinical trial recruitment through relationship building.
An MSL, or Medical Science Liaison, is a scientific or disease state expert employed by healthcare companies to establish relationships with key opinion leaders (KOLs), who are influential doctors. MSLs hold advanced scientific degrees and provide medical information to both internal colleagues and external doctors. Their primary responsibility is managing relationships with KOLs and educating them on scientific topics. The Medical Science Liaison Society is a non-profit organization dedicated to advancing the MSL profession globally.
Medical Affairs, as a function, sits at a crossroads in the pharmaceutical industry. The department is expected to act as a bridge between the commercial and scientific arms of an organization. Medical Affairs is further tasked with being the conduit of information between the company and external stakeholders, bringing efficacy and safety data to the medical community as well as gathering insights from the medical community to share internally. All responsibilities must be undertaken while keeping in mind strict regulatory controls and ensuring that medical data are interpreted appropriately.
ISR has designed this report to be used as a benchmarking tool for companies to compare their Medical Affairs functions to those of Top 50 pharmaceutical organizations.
See more: http://bit.ly/medaffairs
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
This document provides an introduction to medico-marketing, which aims to promote pharmaceutical products. It discusses the objectives of medico-marketing such as launching new products, developing brand image, and spreading awareness of products. Common forms of marketing discussed include sales representatives, drug samples, continuing medical education events, and promotional trials. The document also outlines ethics in medico-marketing, such as only promoting approved products accurately. Several unethical practices are defined, like exaggeration of claims, gifts to promote products, and cash grants to medical practitioners.
Aligning the Activities and Goals of Field Based Teams for
Strengthened Corporate Sustainability
• Examining the disconnect between field based medical and corporate initiatives
• Acquiring and synthesizing field insights to drive clinical and corporate decision-making
• Demonstrating value of the expensive MSL and Advisor roles to the company
The Medical Science Liaison role is growing and being utilized in a number of various ways by different companies. This presentation discussed how they are being utilized.
The document discusses the role and responsibilities of Medical Affairs departments within pharmaceutical companies. It describes how Medical Affairs operates medical information functions, provides insights from research to brand teams, cultivates relationships with key opinion leaders, and oversees publication planning and medical writing. Medical Affairs contributes to promotional review and provides market intelligence. The functions of Medical Affairs are organized globally and sometimes by business unit or therapeutic area at the local level. Key areas of specialization within Medical Affairs include medical services, medical research, and medical liaisons.
Method, tools and recommendations to boost Medical Science Liaisons Competence and performance.
Presentation of best practices to manage key opinion leaders
Medical affairs department for small organizationDr. Zubair Ali
The document summarizes the drug development process and the role of medical affairs departments within pharmaceutical companies. It discusses the various phases of clinical drug trials from phase I to phase IV. It then outlines the structure and responsibilities of medical affairs, including clinical research, pharmacovigilance, medical information services, statistics management, and providing medical support to marketing and sales teams. A key part of medical affairs is the medical science liaison program which aims to educate medical professionals and support clinical trial recruitment through relationship building.
An MSL, or Medical Science Liaison, is a scientific or disease state expert employed by healthcare companies to establish relationships with key opinion leaders (KOLs), who are influential doctors. MSLs hold advanced scientific degrees and provide medical information to both internal colleagues and external doctors. Their primary responsibility is managing relationships with KOLs and educating them on scientific topics. The Medical Science Liaison Society is a non-profit organization dedicated to advancing the MSL profession globally.
Medical Affairs, as a function, sits at a crossroads in the pharmaceutical industry. The department is expected to act as a bridge between the commercial and scientific arms of an organization. Medical Affairs is further tasked with being the conduit of information between the company and external stakeholders, bringing efficacy and safety data to the medical community as well as gathering insights from the medical community to share internally. All responsibilities must be undertaken while keeping in mind strict regulatory controls and ensuring that medical data are interpreted appropriately.
ISR has designed this report to be used as a benchmarking tool for companies to compare their Medical Affairs functions to those of Top 50 pharmaceutical organizations.
See more: http://bit.ly/medaffairs
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
This document provides an introduction to medico-marketing, which aims to promote pharmaceutical products. It discusses the objectives of medico-marketing such as launching new products, developing brand image, and spreading awareness of products. Common forms of marketing discussed include sales representatives, drug samples, continuing medical education events, and promotional trials. The document also outlines ethics in medico-marketing, such as only promoting approved products accurately. Several unethical practices are defined, like exaggeration of claims, gifts to promote products, and cash grants to medical practitioners.
Aligning the Activities and Goals of Field Based Teams for
Strengthened Corporate Sustainability
• Examining the disconnect between field based medical and corporate initiatives
• Acquiring and synthesizing field insights to drive clinical and corporate decision-making
• Demonstrating value of the expensive MSL and Advisor roles to the company
The Medical Science Liaison role is growing and being utilized in a number of various ways by different companies. This presentation discussed how they are being utilized.
Strategic Medical Affairs in pharma and medical devicesAnjan Banerjee
Strategic medical affairs in pharma and medical devices outlines key drivers influencing the growing role of medical affairs functions. Regulatory requirements, demand for local excellence, and the need for transparency are pushing medical activities to expand in areas like medical strategy, clinical operations, and regulatory submissions. Medical affairs contributes throughout the product lifecycle by collecting and disseminating knowledge to internal and external audiences, and can help integrate products into healthcare systems from drug development to reimbursement.
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Manny Garcia MD
This report provides benchmarks and metrics for medical science liaison (MSL) teams at pharmaceutical and medical device companies. It examines MSL activities in areas like thought leader management, supporting medical/clinical teams, education, and performance measurement. The report is based on surveys of over 30 companies and contains over 160 charts and tables analyzing MSL metrics across different company sizes and regions. It aims to help companies improve coordination of MSL activities and demonstrate their value.
This presentation gives an insight into the membership benefits of Best Practices, LLC’s Medical Affairs Consortium. It also highlights some of the key benchmarks and best practices that emerged from Medical Affairs Consortium.
The Medical Affairs Consortium at Best Practices, LLC provides a dedicated platform to Medical Affairs Leaders to discuss top challenges, develop action oriented solutions, share best practices & lessons learned and explore current and future trends with regards to the Medical Affairs function and its interactions with other critical functions.
Topics for the Medical Affairs Consortium are usually determined by member requests. The Medical Affairs Consortium addresses three key areas:
• Building Strong Medical Affairs Capabilities
• Medical Affairs Launch Support Excellence
• Medical Affairs’ Critical Role in Health Economics & Outcomes Research
Pharmaceutical Marketing - Whats in store for patients?brandsynapse
This document discusses trends in pharmaceutical marketing and advertising spending from 1996 to 2010. Key points include:
- U.S. pharmaceutical ad spending peaked at $5.4 billion in 2006 but has declined each year since to $4.3 billion in 2010 due to fewer blockbuster drugs, a smaller new drug pipeline, and cost cutting.
- The top spender in 2010 was Pfizer at $967.5 million, though its drug Lipitor will go off patent in 2011. Other top drugs like Plavix and Singulair will also lose patent protection.
- As mainstream breakthrough drugs become fewer, pharmaceutical marketers will need to create more value for newer drugs with smaller benefits and target niche patient
The document discusses best practices for pharmaceutical companies in developing and managing relationships with key opinion leaders (KOLs) through medical science liaisons (MSLs). It provides insights from benchmarking research on the roles of MSLs at different stages of product development and lifecycles. Companies must determine MSL field force size based on factors like product lifecycle, thought leader coverage, and franchise objectives. Developing and maintaining KOL relationships is important for gathering market insights and competitive intelligence.
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
In today’s environment, Pharmaceutical companies find themselves in a bind. Until recently, if drugs made over $500 Million in annual revenue within 3 to 5 years of launch, they were considered hugely successful. They were a support to an extensive company portfolio and a component of greater company profit.
However, things have changed. The standards for a successful drug have become much higher and much more dangerous. With so many revenue-producing drugs going off patent, companies are facing large holes in their balance sheets and sales that are increasingly slow.
Plus, with the stakes high and available funds low, pipelines are drying up. Add to this the closer scrutiny of safety issues, the rise of Generics, slower physician acceptance and adoption of new therapies, and the Pharma Industry is in trouble.
More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launch, companies must engage in comprehensive pre-launch planning.
In this report we analyze why launch is increasingly important, the issues involved in pre-launch planning, including key organizational strategies, marketing tactics, regulatory considerations, global issues, and methods for ensuring the most effective plans.
KOL Relationship & Brand Building in Pharma MarketingAnjali Makhijani
Key Opinion Leaders (KOLs) in Pharmaceutical Context are the clinical experts who can play a critical role in influencing the opinion and clinical practice of their peers and also the healthcare organizations. Thus it is important to have KOL Management as a part of the Marketing strategy.
KOL Management is a continuous process that involves identifying the right experts who are interested and aligned with your brand/molecule, profiling their key strengths and segmenting them according to their positions, mindset and collaboration preferences etc.
Involving KOLs throughout the product lifecycle helps in instant feedback, building long-term relationships and customer loyalty in a long run.
“Marketing 2.0” in the pharmaceutical industry is no longer about just saying that our product is different and hoping customers will see it that way. It’s very much about making it so and then about finding our way to engage customers in a “conversation” that helps create the value rather than just promoting it through armies of medical representatives. We need to develop new, end-to-end processes that shape our relationships with physicians, payers, patients and care-givers.
1) The document discusses the increasing number of online touchpoints with customers as health professionals and patients spend more time online. It provides statistics on internet usage and its influence on treatment decisions.
2) It addresses how pharmaceutical companies can connect with customers online given new regulations and guidelines from bodies like the FDA and ABPI.
3) It examines the challenge of managing all the digital assets and activity, both within companies and outside their control, referring to this as "taming the digital sprawl".
From Social Media through to Artificial intelligence...and more. In this presentation I covered the trends that we're currently seeing in Medical Affairs - those trends which are important now, those trends which will impact Medical Affairs in the future, and the skills required to be successful.
To read the LinkedIn article here’s the link: https://www.linkedin.com/pulse/trends-medical-affairs-presented-appa-march-14-2018-glenn-carter/
For further discussion phone us on:
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
Or for additional insights go to one of our specialised websites:
Healthcare Professionals Group
(https://www.hpgconnect.com/)
Health & Aged Care Professionals (https://www.hacpconnect.com/)
Pharmaceutical & Medical Professionals
(https://www.pmpconnect.com/)
Rural & Remote Healthcare Professionals
(https://www.rrhpconnect.com/)
This 3 sentence summary provides the high level and essential information from the document:
The document discusses how pharmaceutical companies can develop effective key opinion leader (KOL) relationship management (KRM) strategies and plans. It explains that while customer relationship management (CRM) focuses on immediate prescription generation, KRM aims to create long-term brand perception and influence among target audiences through KOL activities. The document also outlines some of the key elements that should be included in a robust KRM strategy and plan, such as KOL identification, customized engagement programs, and impact measurement.
This one-day certificate training workshop on pharmaceutical marketing strategy will be held on February 12 in Karachi and February 26 in Lahore. The workshop aims to provide participants grounding in strategic analysis tools for pharmaceutical marketing. Attendees will learn about pharmaceutical marketing strategy, applying the 4 P's, analyzing strengths/weaknesses/opportunities/threats, and developing a long-term marketing plan through scenarios. Successful coordination of marketing requires aligning all activities to patient and physician needs. The workshop will use interactive exercises and cases to help participants contextualize the environment and formulate a coherent marketing strategy.
Competitive Analysis in Pharmaceutical IndustryYee Jie NG
Eli Lilly is a global pharmaceutical company founded in 1876. The document analyzes Eli Lilly's competitive position using Porter's Five Forces and SWOT analysis. It identifies key trends in the pharmaceutical industry including mergers and acquisitions, aging populations, expiring patents, and increased regulations. These trends present both opportunities and threats for Eli Lilly. The analysis suggests Eli Lilly should pursue strategies like partnerships, emerging markets, and ongoing R&D to adapt to changes in the competitive landscape over the next 10 years.
Highlights from ExL Pharma's 6th MSL Best PracticesExL Pharma
This document summarizes key points from ExLPharma's 6th annual MSL Best Practices conference. It discusses the evolving role of medical science liaisons (MSLs) and how they can effectively educate healthcare providers while minimizing compliance risks. The role of MSLs is varied by company but generally involves building scientific relationships with key opinion leaders. The document provides guidance on developing standard operating procedures for MSLs, clarifying their reporting structure, compensation practices, involvement in clinical trials and interactions with sales representatives to reduce promotional concerns. It emphasizes the need for MSL training, oversight and auditing to ensure their activities remain focused on non-promotional scientific exchange.
The Digital Metamorphosis of the Pharma IndustryLen Starnes
The document discusses the digital transformation of the pharmaceutical industry. It notes changes like aging populations, rising healthcare costs, empowered patients, and new business models. Doctors are becoming "digital" and using social networks and mobile devices. Patients are forming online communities to share health data. The document suggests pharmaceutical companies must adapt by using digital tools, empowering sales forces with mobile technology, and building trust with doctors, patients, and online communities. Pharma must learn from the digital behaviors of doctors and patients to keep pace with their evolving expectations.
Visdios is a specialist in key opinion leader management, development, implement process and also manage all kind of KOL solutions across your company. We engage with our valuable customers to get a real understanding of their business requirements.
http://visdios.com/kol-management-india/
Pharmaceutical marketing plan case studyMohamed Magdy
Pharmaceutical Marketing Plan Case Study
I can challenge you will never see such fully fledged Pharmaceutical Marketing Plan Case Study in the internet for FREE as I did in this case study!
Click here to ENJOY it: http://www.guerrillamarketer.com/pharmaceutical-marketing-plan-case-study/
While the role of medical science liaisons (MSLs) has grown substantially in recent years, training opportunities have not kept pace. Most MSLs receive little formal training from their employers. However, MSLs themselves report a strong need for additional training, particularly in soft skills like presentation and communication. The MSL Society aims to address this gap by providing online and live training programs focused on topics such as emotional intelligence that can help MSLs succeed in their important roles.
The document discusses marketing management in the pharmaceutical industry. It provides insights into the roles and responsibilities of marketers and brand managers in the industry. It discusses key aspects of marketing management including market research, forecasting, business modeling, communication strategies, training sales teams, monitoring results, and working with third party agencies. It also provides data on the Pakistani pharmaceutical market size and growth of top companies. Global prevalence data and projections for hypertension are presented to illustrate how marketers select markets to serve.
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Best Practices
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
Strategic Medical Affairs in pharma and medical devicesAnjan Banerjee
Strategic medical affairs in pharma and medical devices outlines key drivers influencing the growing role of medical affairs functions. Regulatory requirements, demand for local excellence, and the need for transparency are pushing medical activities to expand in areas like medical strategy, clinical operations, and regulatory submissions. Medical affairs contributes throughout the product lifecycle by collecting and disseminating knowledge to internal and external audiences, and can help integrate products into healthcare systems from drug development to reimbursement.
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Manny Garcia MD
This report provides benchmarks and metrics for medical science liaison (MSL) teams at pharmaceutical and medical device companies. It examines MSL activities in areas like thought leader management, supporting medical/clinical teams, education, and performance measurement. The report is based on surveys of over 30 companies and contains over 160 charts and tables analyzing MSL metrics across different company sizes and regions. It aims to help companies improve coordination of MSL activities and demonstrate their value.
This presentation gives an insight into the membership benefits of Best Practices, LLC’s Medical Affairs Consortium. It also highlights some of the key benchmarks and best practices that emerged from Medical Affairs Consortium.
The Medical Affairs Consortium at Best Practices, LLC provides a dedicated platform to Medical Affairs Leaders to discuss top challenges, develop action oriented solutions, share best practices & lessons learned and explore current and future trends with regards to the Medical Affairs function and its interactions with other critical functions.
Topics for the Medical Affairs Consortium are usually determined by member requests. The Medical Affairs Consortium addresses three key areas:
• Building Strong Medical Affairs Capabilities
• Medical Affairs Launch Support Excellence
• Medical Affairs’ Critical Role in Health Economics & Outcomes Research
Pharmaceutical Marketing - Whats in store for patients?brandsynapse
This document discusses trends in pharmaceutical marketing and advertising spending from 1996 to 2010. Key points include:
- U.S. pharmaceutical ad spending peaked at $5.4 billion in 2006 but has declined each year since to $4.3 billion in 2010 due to fewer blockbuster drugs, a smaller new drug pipeline, and cost cutting.
- The top spender in 2010 was Pfizer at $967.5 million, though its drug Lipitor will go off patent in 2011. Other top drugs like Plavix and Singulair will also lose patent protection.
- As mainstream breakthrough drugs become fewer, pharmaceutical marketers will need to create more value for newer drugs with smaller benefits and target niche patient
The document discusses best practices for pharmaceutical companies in developing and managing relationships with key opinion leaders (KOLs) through medical science liaisons (MSLs). It provides insights from benchmarking research on the roles of MSLs at different stages of product development and lifecycles. Companies must determine MSL field force size based on factors like product lifecycle, thought leader coverage, and franchise objectives. Developing and maintaining KOL relationships is important for gathering market insights and competitive intelligence.
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
In today’s environment, Pharmaceutical companies find themselves in a bind. Until recently, if drugs made over $500 Million in annual revenue within 3 to 5 years of launch, they were considered hugely successful. They were a support to an extensive company portfolio and a component of greater company profit.
However, things have changed. The standards for a successful drug have become much higher and much more dangerous. With so many revenue-producing drugs going off patent, companies are facing large holes in their balance sheets and sales that are increasingly slow.
Plus, with the stakes high and available funds low, pipelines are drying up. Add to this the closer scrutiny of safety issues, the rise of Generics, slower physician acceptance and adoption of new therapies, and the Pharma Industry is in trouble.
More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launch, companies must engage in comprehensive pre-launch planning.
In this report we analyze why launch is increasingly important, the issues involved in pre-launch planning, including key organizational strategies, marketing tactics, regulatory considerations, global issues, and methods for ensuring the most effective plans.
KOL Relationship & Brand Building in Pharma MarketingAnjali Makhijani
Key Opinion Leaders (KOLs) in Pharmaceutical Context are the clinical experts who can play a critical role in influencing the opinion and clinical practice of their peers and also the healthcare organizations. Thus it is important to have KOL Management as a part of the Marketing strategy.
KOL Management is a continuous process that involves identifying the right experts who are interested and aligned with your brand/molecule, profiling their key strengths and segmenting them according to their positions, mindset and collaboration preferences etc.
Involving KOLs throughout the product lifecycle helps in instant feedback, building long-term relationships and customer loyalty in a long run.
“Marketing 2.0” in the pharmaceutical industry is no longer about just saying that our product is different and hoping customers will see it that way. It’s very much about making it so and then about finding our way to engage customers in a “conversation” that helps create the value rather than just promoting it through armies of medical representatives. We need to develop new, end-to-end processes that shape our relationships with physicians, payers, patients and care-givers.
1) The document discusses the increasing number of online touchpoints with customers as health professionals and patients spend more time online. It provides statistics on internet usage and its influence on treatment decisions.
2) It addresses how pharmaceutical companies can connect with customers online given new regulations and guidelines from bodies like the FDA and ABPI.
3) It examines the challenge of managing all the digital assets and activity, both within companies and outside their control, referring to this as "taming the digital sprawl".
From Social Media through to Artificial intelligence...and more. In this presentation I covered the trends that we're currently seeing in Medical Affairs - those trends which are important now, those trends which will impact Medical Affairs in the future, and the skills required to be successful.
To read the LinkedIn article here’s the link: https://www.linkedin.com/pulse/trends-medical-affairs-presented-appa-march-14-2018-glenn-carter/
For further discussion phone us on:
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
Or for additional insights go to one of our specialised websites:
Healthcare Professionals Group
(https://www.hpgconnect.com/)
Health & Aged Care Professionals (https://www.hacpconnect.com/)
Pharmaceutical & Medical Professionals
(https://www.pmpconnect.com/)
Rural & Remote Healthcare Professionals
(https://www.rrhpconnect.com/)
This 3 sentence summary provides the high level and essential information from the document:
The document discusses how pharmaceutical companies can develop effective key opinion leader (KOL) relationship management (KRM) strategies and plans. It explains that while customer relationship management (CRM) focuses on immediate prescription generation, KRM aims to create long-term brand perception and influence among target audiences through KOL activities. The document also outlines some of the key elements that should be included in a robust KRM strategy and plan, such as KOL identification, customized engagement programs, and impact measurement.
This one-day certificate training workshop on pharmaceutical marketing strategy will be held on February 12 in Karachi and February 26 in Lahore. The workshop aims to provide participants grounding in strategic analysis tools for pharmaceutical marketing. Attendees will learn about pharmaceutical marketing strategy, applying the 4 P's, analyzing strengths/weaknesses/opportunities/threats, and developing a long-term marketing plan through scenarios. Successful coordination of marketing requires aligning all activities to patient and physician needs. The workshop will use interactive exercises and cases to help participants contextualize the environment and formulate a coherent marketing strategy.
Competitive Analysis in Pharmaceutical IndustryYee Jie NG
Eli Lilly is a global pharmaceutical company founded in 1876. The document analyzes Eli Lilly's competitive position using Porter's Five Forces and SWOT analysis. It identifies key trends in the pharmaceutical industry including mergers and acquisitions, aging populations, expiring patents, and increased regulations. These trends present both opportunities and threats for Eli Lilly. The analysis suggests Eli Lilly should pursue strategies like partnerships, emerging markets, and ongoing R&D to adapt to changes in the competitive landscape over the next 10 years.
Highlights from ExL Pharma's 6th MSL Best PracticesExL Pharma
This document summarizes key points from ExLPharma's 6th annual MSL Best Practices conference. It discusses the evolving role of medical science liaisons (MSLs) and how they can effectively educate healthcare providers while minimizing compliance risks. The role of MSLs is varied by company but generally involves building scientific relationships with key opinion leaders. The document provides guidance on developing standard operating procedures for MSLs, clarifying their reporting structure, compensation practices, involvement in clinical trials and interactions with sales representatives to reduce promotional concerns. It emphasizes the need for MSL training, oversight and auditing to ensure their activities remain focused on non-promotional scientific exchange.
The Digital Metamorphosis of the Pharma IndustryLen Starnes
The document discusses the digital transformation of the pharmaceutical industry. It notes changes like aging populations, rising healthcare costs, empowered patients, and new business models. Doctors are becoming "digital" and using social networks and mobile devices. Patients are forming online communities to share health data. The document suggests pharmaceutical companies must adapt by using digital tools, empowering sales forces with mobile technology, and building trust with doctors, patients, and online communities. Pharma must learn from the digital behaviors of doctors and patients to keep pace with their evolving expectations.
Visdios is a specialist in key opinion leader management, development, implement process and also manage all kind of KOL solutions across your company. We engage with our valuable customers to get a real understanding of their business requirements.
http://visdios.com/kol-management-india/
Pharmaceutical marketing plan case studyMohamed Magdy
Pharmaceutical Marketing Plan Case Study
I can challenge you will never see such fully fledged Pharmaceutical Marketing Plan Case Study in the internet for FREE as I did in this case study!
Click here to ENJOY it: http://www.guerrillamarketer.com/pharmaceutical-marketing-plan-case-study/
While the role of medical science liaisons (MSLs) has grown substantially in recent years, training opportunities have not kept pace. Most MSLs receive little formal training from their employers. However, MSLs themselves report a strong need for additional training, particularly in soft skills like presentation and communication. The MSL Society aims to address this gap by providing online and live training programs focused on topics such as emotional intelligence that can help MSLs succeed in their important roles.
The document discusses marketing management in the pharmaceutical industry. It provides insights into the roles and responsibilities of marketers and brand managers in the industry. It discusses key aspects of marketing management including market research, forecasting, business modeling, communication strategies, training sales teams, monitoring results, and working with third party agencies. It also provides data on the Pakistani pharmaceutical market size and growth of top companies. Global prevalence data and projections for hypertension are presented to illustrate how marketers select markets to serve.
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Best Practices
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
Digital strategies in pharmaceutical industryMeghavi Mehta
This document discusses digital strategies in the pharmaceutical industry. It covers how digital technologies have evolved in areas like research and development, manufacturing and supply chains, marketing and sales, and health service delivery. Some key points include: digital technologies can help reduce drug development costs and time through tools like biochips and e-clinical trials; ERP systems and real-time solutions help optimize manufacturing and supply chain operations; e-detailing and e-CRM allow more effective marketing and sales; and e-prescribing, telemedicine, and disease management strategies help improve health service delivery and reduce costs. The conclusion is that digital strategies will be crucial for future success in the pharmaceutical industry.
Digital trends in healthcare and pharma marketingGSW
The document discusses several digital trends that are changing the healthcare landscape, including:
1) The rise of tablet devices like the iPad and their use for sales tools and digital detailing.
2) The growth of mobile applications for healthcare professionals and patients for tasks like decision support, education, and collaboration.
3) The increasing importance of location-based services that make healthcare information and resources more personalized and accessible on demand.
Many pharmaceutical companies still prefer to deal with their stakeholders one-by-one in a controlled way. They are often at their most comfortable dealing with clinical opinion leaders, talking about the benefits of their products. But are they missing a trick?
The document discusses the evolution of medical science liaison (MSL) teams from the 1980s to present day. It describes how MSL teams initially focused on post-marketing activities but now also contribute value to clinical drug development processes like trial design and identification of new indications. The document provides examples of how MSL teams have helped pharmaceutical companies gain regulatory approval faster, lower development costs, and increase drug revenues.
The Medical Science Liaison (MSL) & Social NetworkingStephen Dodge
This document discusses using social networking for hiring, internal collaboration, and customer engagement by medical science liaisons (MSLs). It provides tips for using LinkedIn for recruiting and hiring. It also recommends using social business software like Yammer or Jive to facilitate internal collaboration for non-co-located teams. Finally, it argues that MSLs can engage thought leaders through their presence on networks like LinkedIn, QuantiaMD, and Doximity, as over 30% of thought leaders may already be on such networks. An example virtual community set up by a pharmaceutical company found KOLs had a positive response, though the sample size was small.
This document provides information about the 3rd Annual Medical Affairs Asia Summit taking place from August 26-29, 2014 in Singapore. The summit will feature over 85% new speakers and focus on advancing effective communication and collaboration with internal and external stakeholders. It will include keynote speeches, panel discussions, and workshops on topics like medical affairs strategies, stakeholder engagement, regulatory trends, and collaborating with marketing. The event is aimed at medical affairs professionals in the pharmaceutical and healthcare industries in Asia.
The document summarizes compensation rates for various types of thought leaders and medical professionals providing consulting services to pharmaceutical companies in Europe. It provides average hourly and flat fee ranges for different activities like speaking, advisory panels, and authorships. It also breaks down rates by company size, therapeutic area, and type of thought leader, such as their professional role and specialty. The document was presented by Dr. Samuel Dyer, the CEO and founder of a company that collects data on compensation for medical science liaisons and thought leaders.
Highlights From 7th Medical Science Liaison/MSL ConferenceExL Pharma
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
Roles, Resources, and Managemet of Medical Science LiaisonsBest Practices, LLC
This document summarizes the findings of a benchmarking report on roles, resourcing, and management of medical science liaisons (MSLs). Key findings include determining the optimal number of MSLs based on factors like product lifecycle, market monitoring, and relationship management standards. The report also examines budget allocation, value measurement, and shifting MSL responsibilities in response to changing industry dynamics. Insights are drawn from interviews with leaders from over 20 pharmaceutical companies.
Optimizing KOL Relationships Report SummaryBest Practices
Key Opinion Leaders (KOLs) play a critical role in educating the medical and scientific communities to build awareness about the latest medical therapies and novel mechanisms of action. KOL relationship management has thus emerged as a necessary and vital part of brand success. In an effort to examine how leading pharmaceutical companies approach KOL management, this research by Best Practices, LLC identifies the key elements of KOL management excellence, from structure and strategies to MSL roles and KOL activity assessment.
The document discusses key opinion leader (KOL) identification and selection for pharmaceutical companies. It outlines regulatory guidance requiring transparency in KOL relationships and selection criteria based on medical expertise. The document proposes that citation analysis is an effective method for determining a scientist's influence and peer esteem, as shown by Thomson Reuters' success in predicting Nobel Prize winners based primarily on citations. It provides methods for identifying KOLs based on a company's business needs, such as publication count for new markets or citation analysis for established markets. The document recommends aligning KOLs with development stages, using both established leaders and rising stars.
10 essential questions for successful kol managementexecutiveinsight
The document outlines 10 essential questions for successful KOL management programs. The questions cover defining KOLs, conducting targeted KOL mapping, considering KOL networks not just individuals, defining long-term KOL strategies, building collaborative approaches, dedicating teams to KOL management, using technology to optimize interactions, remunerating KOLs appropriately and transparently, measuring and evaluating KOL interactions, and sharing learnings internally. Successful KOL programs require comprehensive planning and ongoing engagement with a diverse range of stakeholders over the long term.
Digital Marketing Case Study + Consortium DetailsBest Practices
Sample slides from our latest research on Mastering Digital Marketing Structure and Strategy and how it helped the commissioning client transform their multi-channel marketing function.
How to Register? Other Questions? Give us a call or simply fill in the "Get in touch" form and we will be in touch to discuss further.
Best Practices, LLC is a research and consulting firm that provides benchmarking reports and advisory services to pharmaceutical, biotech, and medical device companies. It has nearly two decades of experience working with top companies in these industries. BPLLC's services include conducting research to identify best practices in areas like sales, product development, and medical affairs. It collects both quantitative and qualitative data through surveys and interviews to understand how industry leaders approach various challenges. BPLLC then analyzes the data and presents actionable recommendations and insights to help clients optimize their organizations and outperform competitors. Many of BPLLC's past clients report marked improvements after implementing the strategies and practices it identified.
Centauric is an expert consulting firm that helps organizations unleash the potential of their people to drive business performance. They use a data-driven approach involving interviews, surveys, and facilitated discussions to understand organizational dynamics and identify opportunities. Their integrated services then develop leadership capabilities, strengthen employee engagement, and align culture and systems. The outcomes include increased focus on goals, engaged and committed employees, an innovative culture embracing change, and effective talent selection and development.
This document provides a summary of a report on developing high-performance market research functions. It discusses key findings such as optimizing structures through collaboration, building influence by providing value to all business units, and managing processes and productivity. It also outlines the report's structure and chapters on optimizing structures, building influence, managing processes, and developing talent. Sample practices are presented, such as serving all internal groups to expand influence and tracking business cases to increase productivity.
Advocacy Excellence: Optimizing Group Structure & Operations Report SummaryBest Practices
Patient advocacy groups have evolved into organizations that play a critical role in educating patients. Correspondently, the advocacy function within pharma has grown in importance as collaborations with patient groups are linked to enhanced disease state and brand education among patient groups.
This Best Practices
®, LLC study identifies key trends in how pharma advocacy group serve internal customers and which activities have the most value. Additionally, the study examines the roles and responsibilities of advocacy. Advocacy group leaders can use this study to better align their relationships with internal and external customers.
My Executive Solutions helps organizations achieve cultural transformation through leadership development and employee engagement initiatives. They conduct an organizational assessment involving interviews, focus groups, and surveys to identify areas for improvement. Then they create a customized development plan and implement initiatives like team building sessions, executive coaching, and leadership training over 18 months to foster greater trust, alignment, and commitment across the organization. The goal is to develop a high-performing culture with engaged employees focused on achieving business objectives.
The document introduces the Center for High Performance (CfHP), which helps companies achieve high performance. CfHP works with executive teams to enhance collaboration, stimulate creativity, and improve decision-making. CfHP also helps companies identify and address barriers to high performance. CfHP addresses strategic problems and helps leaders model behaviors of high-performing teams to drive sustainable growth and results.
The document provides information on several leadership development companies in India. It discusses:
1) The leadership identification, assessment, and development solutions offered by the companies to help clients identify and strengthen their current and future leaders. This includes 360 assessments, leadership programs, coaching, and customized solutions.
2) The types of clients served, which include large Indian and multinational corporations.
3) Additional services offered beyond leadership development, such as organizational consulting, change management support, and talent management.
4) Key differentiators of the companies, which emphasize their customized approach, global expertise, and track record of positive outcomes for clients.
Frost Consultant Group is an IT and business advisory services firm based in Allen, Texas that provides confidential consulting services to help clients solve problems and unlock value. The firm has three business units and focuses on providing C-level advisory services, business consulting, and technology consulting to both large and small clients across North America. Frost Consultant Group aims to fill the gap between a client's existing staff and larger consulting organizations by taking a collaborative, problem-solving approach.
Quantix Marketing Consulting Romania Corporate OverviewCosmin Nae
This document summarizes Quantix Marketing Consulting, a young company that provides market research and strategic consulting services. It outlines their team of experienced professionals, flexible boutique structure, and partnership business model. Quantix works closely with clients to understand their issues, design appropriate research, ensure valid results, and provide actionable insights. Their goal is to go beyond typical reports and offer bundled research, consulting, and strategic services to help organizations make better decisions with their marketing budgets.
Roundhouse Consulting Limited is a specialist organization development consultancy that works with organizations of all sizes and sectors to design effective operating models and structures, manage change, and develop talent and leadership. They take a collaborative approach and focus on building client capability. Their services include facilitating strategy alignment, designing operating models, and integrating people strategies into change projects for faster and more successful transformations.
The Newman Group, a Futurestep company, provides three key services for talent management:
1) Talent acquisition strategic assessment and solutions to help streamline recruitment processes and control costs.
2) Workforce planning consulting to assist with developing strategic workforce plans, analyzing talent needs, and gaining a competitive advantage.
3) Integrated talent management (ITM) business planning to help operationalize a talent strategy through a 120-day planning process addressing talent acquisition, learning and development, succession planning, and other disciplines.
The document outlines Apricot Global's vision, mission, and core values which focus on inspiring creativity, achieving excellence, building trust, acting with an entrepreneurial spirit, stretching people to develop a "can do" attitude, creating long-term relationships with a focus on execution excellence, mobilizing skilled teams to deliver exceptional results, valuing diversity and ensuring an inclusive environment, and inspiring trust through responsible and ethical actions. It also discusses Apricot Global's commitment to corporate governance and involvement in local communities.
This document summarizes the vision, mission, motivations, and services of a strategic advisory and consulting firm. The firm brings trans-disciplinary talent and expertise to help leaders achieve sustainable growth through quality decisions. They partner with leaders, bringing innovative, creative, and contextually relevant solutions to governance, strategy, projects, and communications challenges. The firm is passionate about solving business problems through a holistic approach considering business processes, people, organization, and technology.
Company profile trustpartners april 2013TrustPartners
TrustPartners is an Italian management consulting firm with expertise in highly regulated industries. It provides business planning, performance management, and organizational consulting. The firm has deep experience in pharmaceuticals, energy, gaming/gambling, tobacco, and public administration. It offers strategic support, process optimization, and change management assistance to improve clients' performance. TrustPartners works with companies across Italy from its headquarters in Rome and branch in Milan.
Organisation Change, Management Development & Communications Consulting and T...journal72
Its services include organization analysis, strategy analysis, people analysis, systems analysis, and transformation programs to drive successful organization changes.
The document discusses the objectives and methods of Instituto Yiesia, which includes provoking companies to reflect and reinvent themselves, identifying best practices, and relying on knowledge of corporate governance and compliance. It aims to be recognized as a stimulating intermediary that enables transformation. The institute provides advice to companies on increasing effectiveness, improving competition, and contributing to sustainability and protecting reputation through a holistic and customized approach.
This is the institutional presentation of Instituto Yiesia of Corporate Governance and Compliance. Instituto Yiesia renders advisory services aiming at generating value to companies through corporate governance instruments. Private Equity and Venture Capital Funds may benefit from it in the fund raising process. Hope you all enjoy it. Reinvent your company, gain market share, promote the sustainability of your business, achieve another step of leadership among peers. Even if it´s not your intention to sell your company, do an IPO or even get an institutional parter, it´s always advisable to see your company as a "liquid investment" when your corporate governance and compliance practices are all in place. Take advantage of it!
How a corporate governance and compliance framework is able to generate added value to any company
Sarvagnya is a strategic HR and OD consulting firm founded on 20 years of global experience. It provides services such as change management, competency modeling, learning and development, business process engineering, HR policies/processes, and performance management. The firm uses proprietary tools and a scientific approach to address organizational challenges. It has experience across multiple industries and geographies. The management team is led by Sri Harsha, who has over 20 years of experience in strategic HR and business consulting.
Shaking the Box: Creating Indelible Organizational Change kirkholmes11
How do you drive organizational change when massive cultural change is needed? This presentation includes examples of techniques and approaches based on an 8 step model created by J.P. Kotter. This model is very useful for best practices implementations like ITIL or CMMI, process process improvement, quality programs, performance management, reducing costs, and improving competitiveness.
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Best Practices
It has become quite crucial to identify the drivers of digital marketing performance excellence in the health care industry which will enable companies to gain valuable customer insights, build effective relationships, leverage online media, and maximize revenue.
Best Practices, LLC undertook this benchmarking research to provide critical insights into how savvy bio-pharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs and optimizing insource vs. outsource mix.
Download Full Report: http://bit.ly/2gnXrIu
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Best Practices
This document summarizes a benchmarking study of new product planning structures and activities at 15 pharmaceutical and biotech companies. Key findings include:
- Global teams transition from planning to marketing earlier than regional teams.
- Global teams begin branding activities like naming in phase II, while regional teams start in phase III.
- Global teams value segmentation and positioning most, while regional teams value market research.
- Global new product planning is more centralized while regional structures are more hybrid.
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
This document summarizes a study examining best practices for collaborating with patient advocacy groups. It provides an overview of the research methodology, participating companies, key findings and insights. Some of the main findings include: 1) there is no single best structure for patient advocacy groups, with companies taking decentralized, centralized and hybrid approaches; 2) social media and video platforms are increasingly important in patient education; and 3) transparency, aligning objectives, and trust are critical when working with advocacy groups on controversial therapies.
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Best Practices
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Best Practices
This document provides a summary of a benchmarking study conducted by Best Practices, LLC on medical education structures, resources, and activities at major biopharmaceutical companies. Some key findings include:
- Most companies (over 75%) take a centralized approach to organizing their medical education functions. Nearly half centralize in the US.
- Companies heavily rely on outsourcing, delegating 86% of program development and all program deployment to vendors.
- Respondents were primarily directors or senior directors of medical education functions, with some managers. Insights were drawn from leaders across various roles and geographies.
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Best Practices
Medical education programs play an important role in informing health care professionals about the safe and effective use of medical devices.
To probe emerging medical education trends in the device sector, Best Practices, LLC undertook benchmarking research. In particular, this study provides benchmarks on the proper size, structure, funding channels, staffing and investment for medical education groups.
Download Full Report: http://bit.ly/2bY2NZ8
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. Therefore, it is absolutely critical for bio-pharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
According to recent research by Best Practices, LLC, nearly three-quarters of the benchmarked study participants use review cycle time as a metric for determining if the market research approval process is functioning at an acceptable level. One tip that participants gave on how to control processes and to ensure high performance is to create checklists. Begin with checklists in pinch points that are most problematic, and then extend to entire process and operations. This report will help leaders to gain critical insights they need to compete successfully in a fast-changing market.
Download Full Report: http://bit.ly/2bfAhOc
Benchmarking Professional Medical Education Excellence StructuresBest Practices
This document summarizes a benchmarking study conducted by Best Practices, LLC on medical education structures, resources, and activities at large biopharmaceutical companies. Key findings include:
- Most companies take a centralized approach to medical education, located in their US market or headquarters country.
- Companies rely heavily on outsourcing, using vendors for 53% of program development and 58% of program delivery on average.
- Staffing is concentrated in North America, with an average of 5 FTEs and $3.23 million budget per FTE. Companies support an average of 170 CME and 98 non-CME programs annually.
Given the stringent regulatory requirements in the health care industry, it is important for bio-pharmal companies to develop innovative Risk Evaluation and Mitigation Strategies (REMS) plans during the commercialization of certain products to ensure an acceptable risk-to-benefit ratio.
This benchmark study published by Best Practices, LLC examines how companies develop and execute successful Risk Evaluation and Mitigation Strategies (REMS) plans for newly-approved drugs in the U.S. market. This study can help bio-pharma companies in creating successful REMS programs.
Download Full Report: http://bit.ly/2aOt5Id
Budget Allocation for a Successful Bio-Pharma Product LaunchBest Practices
Bio-Pharma companies can no longer afford to rely solely on past experiences when budgeting for a new product launch in today's fast-changing, highly competitive market. This comprehensive benchmark study by Best Practices, LLC investigates current costs as well as budget and staffing allocations required for a successful drug launch.
This study can help bio-pharma leaders to develop competitive launch and pre-launch activity budgets to ensure successful U.S. market entry for new products.
Download Full Report: http://bit.ly/2aMYron
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Best Practices
This document summarizes research from a benchmarking study of regulatory affairs practices at 32 leading medical device companies. Key findings include:
- Regulatory affairs structures are most commonly centralized, though some utilize decentralized or hybrid models. Larger companies tend towards more decentralized structures.
- Portfolio complexity, defined as the ratio of class III products, influences but does not solely determine staffing needs.
- On average, companies file over a dozen submissions annually with European regulators and over 60 submissions with Japanese regulators.
- Regulatory staff spend significant time (over 20% for most companies) managing change notices and documentation.
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...Best Practices
Bio-pharmaceutical companies use disease state awareness campaigns to disseminate unbranded information to external stakeholders such as physicians, patients and payers.
Best Practices, LLC undertook research to deliver benchmarks around the structure, timing, investment and activities for disease awareness programs.
Download Full Report: http://bit.ly/2a7CnUS
Library Services Benchmarks - Using Corporate Library Services in PharmaBest Practices
Libraries are custodians of invaluable information. The study - Library Services Benchmarks 2016: Corporate Library Services in the Pharmaceutical Industry published by Best Practices, LLC examines the trends and staffing benchmarks such as library staff per potential and actual users across companies providing access to library services across the bio-pharmaceutical space.
This study looks into staff with formal education level and the number of staff inside and outside the library who provide library services. This study can be used by bio-pharmaceutical companies to improve upon existing library services and staffing.
Download Full Report: http://bit.ly/29QZcbM
Effective Launch Training Practices for District Sales Managers: Optimize Per...Best Practices
Rising competition and access restrictions in the bio-pharmaceutical industry have made it critical for companies to prepare and measure the performance of their District Sales Managers (DMs) who oversee launch-related activities in the field.
Best Practices, LLC engaged 20 sales leaders from bio-pharmaceutical companies to establish benchmarks around the training and accountability of District Sales Managers at launch. Insights from this study will serve as a reference point for companies to evaluate their launch training programs for the sales force against industry benchmarks.
Download Full Report: http://bit.ly/29Gq68L
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices
In order to develop an effective global branding program for new bio-pharmaceutical products, it is important to ensure brand consistency across all functions and geographies.
Best Practices, LLC undertook research to gather benchmarks on key aspects of the global branding process, including activities, timing, positioning, key message development, regional alignment, agency utilization & cost and the tradename process.
Download Full Report: http://bit.ly/2a1XqUV
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Best Practices
The document provides a summary of research conducted on benchmarking advisory board management practices at mid-sized pharmaceutical and medical device organizations. Key findings from surveying 35 executives at 29 companies include that mid-sized companies have more advisory board participants on average compared to other companies, prefer national participants for clinical advisory boards, and face challenges in selecting appropriate advisory board members and managing advisory boards. The research was conducted to identify best practices for advisory board structure, selection of participants, operations, costs, and challenges.
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Best Practices
This document provides a summary of research on developing high-impact communication forms to brief senior leaders on competitive assessments and clinical development summaries. It describes the research methodology, which included surveys and interviews with leaders from 27 bio-pharma companies. Key findings include that executive briefs should be concise (5 pages or less), include general market insights as well as competitor insights, and be created for both new and existing products. Important elements to include are the condition treated, compound name, revenue projections, and probability of success. The document provides templates and recommendations for crafting impactful competitive landscape assessments and clinical development summaries.
Optimizing the Managed Markets Function: Roles, Structures, Resources and Act...Best Practices
This document summarizes the results of a benchmarking analysis that assessed the operational performance of managed markets functions at small and mid-sized pharmaceutical companies. The analysis found that on average these companies dedicate 55% of staff time to account management. It also found that companies feel they could operate with leaner structures, as the perceived ideal ratio of account managers to area directors is lower than current ratios. Additionally, the analysis showed that while account manager compensation is tied 50-50 to MBO and sales plan attainment, area directors compensation weighting shifts more to MBO at 60-40.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.